Company: TVRD
Filing Date: 2025-01-17
Form Type: 425
Source: 0001104659-25-004519
Chunk: 3

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-17
Form: 425
Chunk 3
---
 the Nasdaq Capital Market.

While the Company is making every effort to regain compliance prior
to the extended deadline, there can be no assurance that the Company will be able to regain compliance within the extension period, by
consummation of the Merger or otherwise, and maintain its listing on the Nasdaq Capital Market. If the Company does not regain compliance
within the extension period, or if the Company fails to satisfy another Nasdaq requirement for continued listing, the Staff could provide
notice that the Company’s securities will become subject to delisting. In such event, Nasdaq rules would permit the Company to appeal
the delisting determination to a Nasdaq Hearings Panel. The hearing request would ordinarily stay any suspension or delisting action pending
the conclusion of the hearing process and the expiration of any additional extension period granted by the panel following the hearing,
but there can be no assurance that any such appeal would be successful.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this Current Report on Form 8-K regarding
matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Examples of these forward-looking statements include statements regarding the Company’s plans, assumptions,
expectations, beliefs and objectives with respect the Company’s intent or ability to regain compliance with the Stockholders’
Equity Requirement, the Company’s ability to successfully appeal a delisting determination if issued, the ability of the Company
to comply with the listing requirements of Nasdaq and the ability of the parties to consummate the Merger on the expected timeline or
at all.

Because such statements are subject to risks and uncertainties, actual
results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are
subject to a number of risks, including those factors discussed in the Company’s filings with the Securities and Exchange Commission,
including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ending December 31, 2023,
and its other documents subsequently filed with or furnished to the Securities and Exchange Commission, including its Form 10-Q for the
quarter ended September 30, 2024. All forward-looking statements contained in this Current Report on Form 8-K speak only as of the date
on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances
that exist after the date on which they were made